s-1743 and 1-2-distearoylphosphatidylethanolamine

The mononuclear phagocyte system (MPS) presents a formidable obstacle that hampers the delivery of various nanopreparations to tumors. Therefore, there is an urgent need to improve the off-MPS targeting ability of nanomedicines. In the present study, we present a novel preconditioning strategy to substantially increase the circulation times and tumor targeting of nanoparticles by regulating nanocarrier-MPS interactions.. In vitro, the effect of different vacuolar H. In vitro, ESO was found to reduce the interactions between macrophages and c(RGDm7)-modified vesicles by interfering with the latter's lysosomal trafficking. Studies conducted in vivo confirmed that ESO pretreatment greatly decreased the liver and spleen distribution of the targeted vesicles, enhanced their tumor accumulation, and improved the therapeutic outcome of the drug-loaded nanomedicines.. Our findings indicate that ESO can regulate the nanoparticle-MPS interaction, which provides a feasible option for enhancing the off-MPS targeting of nanomedicines.

Topics: A549 Cells; Animals; Antineoplastic Agents; Biological Transport; Cell Death; Cell Survival; Doxorubicin; Drug Carriers; Endocytosis; Esomeprazole; Humans; Lysosomes; MCF-7 Cells; Mice; Mice, Nude; Mononuclear Phagocyte System; Nanoparticles; Neoplasms; Phosphatidylethanolamines; Polyethylene Glycols; RAW 264.7 Cells; Tissue Distribution; Vacuolar Proton-Translocating ATPases